The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial
Abstract
Importance: Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class with in vitro activity against clinically important gram-negative, gram-positive aerobic, and facultative bacteria including most of those resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug resistant strains and carbapenem-resistant Enterobacteriaceae, and most anaerobic pathogens. Objective: To evaluate the efficacy and safety of eravacycline compared with ertapenem in adult hospitalized patients with complicated intra-abdominal infections (cIAIs). Design, Setting, and Participants: This was a phase III, randomized, double-blind, multicenter study that evaluated the efficacy and safety of eravacycline in comparison with ertapenem in patients with cIAI requiring surgical or percutaneous intervention. The test-of-cure evaluation was conducted 25 to 31 days after the first dose of the study drug and the follow-up visit was conducted 38 to 50 days after the first dose of the study drug. All patients recruited into this study were hospitalized. Five hundred forty-one patients were recruited for this study; 270 patients were randomized to receive eravacycline, and 271 patients were randomized to receive ertapenem. Patients had to meet all of the following criteria: hospitalized for cIAI requiring intervention; 18 years or older; evidence of systemic inflammatory response; pain caused by cIAI; able to provide informed consent; and diagnosis of cIAI with sonogram or radiographic imaging or visual confirmation. Analyses were done in intent-to-treat and evaluable populations. Interventions: Patients received eravacycline, 1.0 mg/kg every 12 hours, or ertapenem, 1.0 g every 24 hours, for a minimum of four 24-hour dosing cycles. Main Outcomes and Measures: Clinical outcome assessments were made at the end of treatment, test of cure, and follow-up visits and were classified as clinical cure, clinical failure, or indeterminate/missing. Results: In total, 541 patients were randomly assigned to treatment: 270 in the eravacycline group and 271 in the ertapenem group. The mean ages were 54.9 years and 55.4 years for the eravacycline and ertapenem groups, respectively. Most patients were white (263 of 270 patients [97.4%] in the eravacycline group and 260 of 271 patients [95.9%] in the ertapenem group). For the microbiological intent-to-treat population, the rates of clinical cure at the test-of-cure visit were 86.8% in the eravacycline group and 87.6% in the ertapenem group. The difference in clinical cure rates between the groups was -0.80% (95% CI, -7.1% to 5.5%), meeting the prespecified noninferiority margin and allowing for statistical noninferiority of eravacycline to ertapenem to be declared for this study. Both study drugs were well tolerated. Conclusions and Relevance: Overall, eravacycline demonstrated noninferiority to ertapenem for the treatment of patients with cIAI. Trial Registration: Clinicaltrials.gov Identifier: NCT01844856.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Mangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C., & Jarvis, W. R. (1999) · PubMed · Cited by 2,783
Potron, A., Poirel, L., & Nordmann, P. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.001 · Cited by 688
Tetracycline antibiotics and resistance mechanisms
Nguyen, F., Starosta, A. L., Arenz, S., Sohmen, D., Dönhöfer, A., & Wilson, D. N. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0292 · Cited by 528
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Self-citationMazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw133 · Cited by 393
Teillant, A., Gandra, S., Barter, D., Morgan, D. J., & Laxminarayan, R. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00270-4 · Cited by 379
Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.
Andersen, B. R., Kallehave, F. L., & Andersen, H. K. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001439.pub2 · Cited by 318
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., et al. (2016) · Drugs · doi:10.1007/s40265-016-0545-8 · Cited by 317
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Metadata
- Authors
- Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P.
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2017-03-01
- Volume
- 152
- Issue
- 3
- Pages
- 224
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W2550643720
- Cited by
- 276
- References
- 23
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamasurg.2016.4237
- The paper
- Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017). Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surgery. https://doi.org/10.1001/jamasurg.2016.4237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.